Nascent Biotech Stock Performance
| NBIO Stock | USD 0.06 0.0002 0.32% |
Nascent Biotech holds a performance score of 7 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 1.72, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nascent Biotech will likely underperform. Use Nascent Biotech potential upside, as well as the relationship between the kurtosis and price action indicator , to analyze future returns on Nascent Biotech.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Nascent Biotech are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent forward indicators, Nascent Biotech displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1435.00 |
Nascent |
Nascent Biotech Relative Risk vs. Return Landscape
If you would invest 4.66 in Nascent Biotech on September 4, 2024 and sell it today you would earn a total of 1.54 from holding Nascent Biotech or generate 33.05% return on investment over 90 days. Nascent Biotech is currently generating 1.0717% in daily expected returns and assumes 11.4977% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Nascent, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nascent Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nascent Biotech's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Nascent Biotech, and traders can use it to determine the average amount a Nascent Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0932
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NBIO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 11.5 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.07 actual daily | 21 79% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Nascent Biotech is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nascent Biotech by adding it to a well-diversified portfolio.
Nascent Biotech Fundamentals Growth
Nascent OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Nascent Biotech, and Nascent Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nascent OTC Stock performance.
| Return On Asset | -0.88 | |||
| Profit Margin | (1.25) % | |||
| Operating Margin | (0.92) % | |||
| Current Valuation | 21.83 M | |||
| Shares Outstanding | 119.56 M | |||
| Price To Earning | 66.00 X | |||
| Price To Book | 6.91 X | |||
| Price To Sales | 21.78 X | |||
| Revenue | 1000 K | |||
| EBITDA | (134.37 K) | |||
| Cash And Equivalents | 145.57 K | |||
| Total Debt | 64.89 K | |||
| Debt To Equity | (1.89) % | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | 413.48 K | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 105.41 K | |||
| Retained Earnings | (17.28 M) | |||
| Current Asset | 522 K | |||
| Current Liabilities | 139 K | |||
About Nascent Biotech Performance
By examining Nascent Biotech's fundamental ratios, stakeholders can obtain critical insights into Nascent Biotech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Nascent Biotech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Nascent Biotech performance evaluation
Checking the ongoing alerts about Nascent Biotech for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Nascent Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nascent Biotech is way too risky over 90 days horizon | |
| Nascent Biotech has some characteristics of a very speculative penny stock | |
| Nascent Biotech appears to be risky and price may revert if volatility continues | |
| Nascent Biotech currently holds 64.89 K in liabilities. Nascent Biotech has a current ratio of 0.11, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nascent Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Nascent Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nascent Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nascent to invest in growth at high rates of return. When we think about Nascent Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 1000 K. Net Loss for the year was (470.39 K) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
| About 32.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Nascent Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nascent Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Nascent Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nascent Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nascent Biotech's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Nascent Biotech's otc stock. These opinions can provide insight into Nascent Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Nascent OTC Stock
Nascent Biotech financial ratios help investors to determine whether Nascent OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nascent with respect to the benefits of owning Nascent Biotech security.